{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:54:06Z","timestamp":1790916846962,"version":"4.1.0"},"reference-count":74,"publisher":"Bentham Science Publishers Ltd.","issue":"18","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["MRMC"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Alzheimer\u2019s disease (AD) is the predominant type of dementia, emerging as a major\nhealth issue globally due to its increasing incidence and the limited approved therapies that provide\nonly symptomatic relief. Adamantane, a diamondoid hydrocarbon with a distinctive cage-like structure,\nhas emerged as a promising scaffold in medicinal chemistry due to its high lipophilicity, leading\nto good central nervous system bioavailability. Notably, memantine, an NMDA (N-methyl-daspartate)\nreceptor antagonist, is an adamantane derivative that is approved by the U.S. Food and\nDrug Administration (US FDA) to manage moderate-to-severe AD symptoms. This review analyses\nthe structure-activity relationship (SAR) of several adamantane derivatives and their relevance to\nAD. Amino-substituted adamantanes, such as amantadine and memantine, display anti-Alzheimer\npotential due to improved NMDA receptor affinity and CNS permeability. Additional targets, such\nas voltage-gated sodium channels and retinoid receptors, are proposed as potential targets for adamantane\nderivatives developed to act against AD. While various adamantane compounds have been\npatented and studied, few have become clinically approved drugs. Structural changes, particularly at\nbridgehead carbon atoms, greatly influence pharmaceutical results. Adamantane's physicochemical\nfeatures make it a preferred framework for future CNS-targeted therapies. Given the increasing need\nfor more effective AD treatments, adamantane-based compounds present a viable option for new\ndrug development.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0113895575426460260130103605","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T19:23:34Z","timestamp":1774034614000},"page":"1449-1459","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Diamonds for the Mind: Exploring the Potential of Adamantane against Alzheimer's Disease"],"prefix":"10.2174","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1640-7986","authenticated-orcid":true,"given":"Preeya","family":"Negi","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, Mumbai, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1832-5366","authenticated-orcid":true,"given":"Nitin Dnyaneshwar","family":"Arote","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, Mumbai, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6803-2912","authenticated-orcid":true,"given":"Vandana Bharat","family":"Patravale","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, Mumbai, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","first-page":"47","volume":"2","author":"Gottfries C.G.","year":"1988","unstructured":"Gottfries C.G.; Alzheimer\u2019s disease. A critical review. Compr Gerontol  1988,2(1),47-62","journal-title":"Compr Gerontol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"e71731","DOI":"10.7759\/cureus.71731","volume":"16","author":"Thakor V.S.","year":"2024","unstructured":"Thakor V.S.; Tyagi A.; Lee J.M.; Coffman F.; Mittal R.; Alois Alzheimer (1864-1915): The father of modern dementia research and the discovery of Alzheimer\u2019s disease. Cureus  2024,16(10),e71731","journal-title":"Cureus"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1177\/089198878800100403","volume":"1","author":"Tonkonogy J.","year":"1988","unstructured":"Tonkonogy J.; Moak G.S.; Alois Alzheimer on presenile dementia. J Geriatr Psychiatry Neurol  1988,1(4),199-206","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"ref=4","first-page":"30","volume":"57","author":"Schneider L.S.","year":"1996","unstructured":"Schneider L.S.; New therapeutic approaches to Alzheimer\u2019s disease. J Clin Psychiatry  1996,57(Suppl. 14),30-36","journal-title":"J Clin Psychiatry"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"102481","DOI":"10.1016\/j.arr.2024.102481","volume":"101","author":"Kamatham P.T.","year":"2024","unstructured":"Kamatham P.T.; Shukla R.; Khatri D.K.; Vora L.K.; Pathogenesis, diagnostics, and therapeutics for Alzheimer\u2019s disease: Breaking the memory barrier. Ageing Res Rev  2024,101,102481","journal-title":"Ageing Res Rev"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1111\/j.1469-1809.1959.tb01473.x","volume":"23","author":"Wheelan L.","year":"1959","unstructured":"Wheelan L.; Familial Alzheimer\u2019s disease. Ann Hum Genet  1959,23(3),300-310","journal-title":"Ann Hum Genet"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1227\/00006123-197905000-00011","volume":"4","author":"Torack R.M.","year":"1979","unstructured":"Torack R.M.; Adult dementia: History, biopsy, pathology. Neurosurgery  1979,4(5),434-442","journal-title":"Neurosurgery"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1002\/alz.13016","volume":"19","year":"2023","unstructured":"Alzheimer\u2019s disease facts and figures. Alzheimers Dement  2023,19(4),1598-1695","journal-title":"Alzheimers Dement"},{"key":"ref=9","year":"2025","unstructured":"Dementia.  Available from:  https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/dementia2025"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"2898","DOI":"10.1002\/alz.12928","volume":"19","author":"Lee J.","year":"2023","unstructured":"Lee J.; Meijer E.; Langa K.M.; Ganguli M.; Varghese M.; Banerjee J.; Khobragade P.; Angrisani M.; Kurup R.; Chakrabarti S.S.; Gambhir I.S.; Koul P.A.; Goswami D.; Talukdar A.; Mohanty R.R.; Yadati R.S.; Padmaja M.; Sankhe L.; Rajguru C.; Gupta M.; Kumar G.; Dhar M.; Chatterjee P.; Singhal S.; Bansal R.; Bajpai S.; Desai G.; Rao A.R.; Sivakumar P.T.; Muliyala K.P.; Bhatankar S.; Chattopadhyay A.; Govil D.; Pedgaonkar S.; Sekher T.V.; Bloom D.E.; Crimmins E.M.; Dey A.B.; Prevalence of dementia in India: National and state estimates from a nationwide study. Alzheimers Dement  2023,19(7),2898-2912","journal-title":"Alzheimers Dement"},{"key":"ref=11","author":"Ray S.","year":"2023","unstructured":"Ray S.; Kumar A.; Kapil S.; Sharma R.; Early detection and management of alzheimer\u2019s disease and dementia in India: A policy perspective.  Available from:  https:\/\/www.semanticscholar.org\/paper\/Early-Detection-%26-Management-of-Alzheimer%E2%80%99s-Disease-Perspective-Ray\/46c7737f47edb5e4443c0ec404eaa91c049828332023"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1212\/CON.0000000000000687","volume":"25","author":"Mendez M.F.","year":"2019","unstructured":"Mendez M.F.; Early-onset alzheimer disease and its variants. Continuum  2019,25(1),34-51","journal-title":"Continuum"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/s13195-021-00927-z","volume":"13","author":"van Bokhoven P.","year":"2021","unstructured":"van Bokhoven P.; de Wilde A.; Vermunt L.; Leferink P.S.; Heetveld S.; Cummings J.; Scheltens P.; Vijverberg E.G.B.; The Alzheimer\u2019s disease drug development landscape. Alzheimers Res Ther  2021,13(1),186","journal-title":"Alzheimers Res Ther"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.tips.2024.05.005","volume":"45","author":"Turgutalp B.","year":"2024","unstructured":"Turgutalp B.; Kizil C.; Multi-target drugs for Alzheimer\u2019s disease. Trends Pharmacol Sci  2024,45(7),628-638","journal-title":"Trends Pharmacol Sci"},{"key":"ref=15","first-page":"208","volume":"109","author":"Rondepierre J.","year":"1951","unstructured":"Rondepierre J.; Baron G.; Hormone therapy in senile dementia. Ann Med Psychol  1951,109(2),208-211","journal-title":"Ann Med Psychol"},{"key":"ref=16","first-page":"263","volume":"76","author":"Bozzi R.","year":"1952","unstructured":"Bozzi R.; Zubiani A.; Use of acetylcholine administered intravenously refracta dosi in the treatment of presenile and senile psychoses. Riv Sper Freniatr Med Leg Alien Ment  1952,76(2),263-268","journal-title":"Riv Sper Freniatr Med Leg Alien Ment"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/j.1532-5415.1974.tb01524.x","volume":"22","author":"Burian E.","year":"1974","unstructured":"Burian E.; An ergot alkaloid preparation (Hydergine) in the treatment of presenile brain atrophy (Alzheimer\u2019s disease): Case report. J Am Geriatr Soc  1974,22(3),126-128","journal-title":"J Am Geriatr Soc"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/S0140-6736(77)92852-5","volume":"310","author":"Perry E.","year":"1977","unstructured":"Perry E.; Perry R.H.; Tomlinson B.E.; Dietary lecithin supplements in dementia of Alzheimer type. Lancet  1977,310(8031),242-243","journal-title":"Lancet"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/0378-4347(92)80602-M","volume":"577","author":"Haginaka J.","year":"1992","unstructured":"Haginaka J.; Seyama C.; Determination of enantiomers of 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine hydrochloride (E2020), a centrally acting acetylcholine esterase inhibitor, in plasma by liquid chromatography with fluorometric detection. J Chromatogr, Biomed Appl  1992,577(1),95-102","journal-title":"J Chromatogr, Biomed Appl"},{"key":"ref=20","year":"2012","unstructured":"ARICEPT\u00ae (donepezil hydr ochloride) tablets.  Available from:  https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/020690s035,021720s008,022568s005lbl.pdf2012"},{"key":"ref=21","year":"2018","unstructured":"EXELON\u00ae (rivastigmine tartrate) capsules, for oral use.  Available from:  https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/020823s036,021025s024lbl.pdf2018"},{"key":"ref=22","year":"2000","unstructured":"Exelon\u00ae Patch (rivastigmine transdermal system).  Available from:  https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2007\/022083lbl.pdf2000"},{"key":"ref=23","year":"2015","unstructured":"RAZADYNE\u00ae ER (galantamine hydrobromide) extended-release capsules, for oral use.  Available from:  https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/021615s021lbl.pdf2015"},{"key":"ref=24","year":"2018","unstructured":"NAMENDA\u00ae (memantine hydrochloride) tablets, for oral use.  Available from:  https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/021487s025lbl.pdf2018"},{"key":"ref=25","year":"2016","unstructured":"MEMANTINE and DONEPEZIL HYDROCHLORIDES extended-release capsules, for oral use.  Available from:  https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/208328orig1s000lbl.pdf2016"},{"key":"ref=26","year":"2021","unstructured":"ADUHELM\u2122 (aducanumab-avwa) injection, for intravenous use.  Available from:  https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761178s000lbl.pdf2021"},{"key":"ref=27","year":"2025","unstructured":"LEQEMBI\u00ae (lecanemab-irmb) injection, for intravenous use.  Available from:  https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761269s005lbl.pdf2025"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/0278-5846(86)90047-3","volume":"10","author":"Fleischhacker W.W.","year":"1986","unstructured":"Fleischhacker W.W.; Buchgeher A.; Schubert H.; Memantine in the treatment of senile dementia of the Alzheimer type. Prog Neuropsychopharmacol Biol Psychiatry  1986,10(1),87-93","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1039\/D1OB01916C","volume":"20","author":"Weigel W.K.","year":"2021","unstructured":"Weigel W.K.; Dang H.T.; Feceu A.; Martin D.B.C.; Direct radical functionalization methods to access substituted adamantanes and diamondoids. Org Biomol Chem  2021,20(1),10-36","journal-title":"Org Biomol Chem"},{"key":"ref=30","year":"2025","unstructured":"Adamantane, \u226599%.  Available from:  https:\/\/www.sigmaaldrich.com\/IN\/en\/product\/aldrich\/100277?srsltid=AfmBOopuIkh0u9WgyG6ygDkg7t-RPXoNNHaH1O1Ui9L_46Wf-Xg0pyTN2025"},{"key":"ref=31","year":"2025","unstructured":"Adamantane.  Available from:  https:\/\/webbook.nist.gov\/cgi\/cbook.cgi?ID=C281232andMask=802025"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1007\/BF00922046","volume":"24","author":"Murakhovskaya A.S.","year":"1975","unstructured":"Murakhovskaya A.S.; Stepanyants A.U.; Bagrii E.I.; Dolgopolova T.N.; Frid T.Y.; Zimina K.I.; Sanin P.I.; Steric effects and additivity of the chemical shifts in the NMR-13C spectra of adamantane derivatives. Bull Acad Sci USSR, Div Chem Sci  1975,24(6),1203-1207","journal-title":"Bull Acad Sci USSR, Div Chem Sci"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"3217","DOI":"10.1021\/acs.jpcc.2c07777","volume":"127","author":"Palczynski K.","year":"2023","unstructured":"Palczynski K.; Kirschbaum T.; Bande A.; Dzubiella J.; Hydration structure of diamondoids from reactive force fields. J Phys Chem C  2023,127(6),3217-3227","journal-title":"J Phys Chem C"},{"key":"ref=34","unstructured":"Indian Patent Advanced Search System.  Available from:  https:\/\/iprsearch.ipindia.gov.in\/publicsearch"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1002\/cber.19410741004","volume":"74","author":"Prelog V.","year":"1941","unstructured":"Prelog V.; Seiwerth R.; On the synthesis of adamantane. Ver Dtsch Chem Ges A B Ser  1941,74(10),1644-1648","journal-title":"Ver Dtsch Chem Ges A B Ser"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1002\/ibra.12098","volume":"9","author":"Tang B.C.","year":"2023","unstructured":"Tang B.C.; Wang Y.T.; Ren J.; Basic information about memantine and its treatment of Alzheimer\u2019s disease and other clinical applications. Ibrain  2023,9(3),340-348","journal-title":"Ibrain"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"015404","DOI":"10.1088\/2053-1591\/ada5ba","volume":"12","author":"R A.","year":"2025","unstructured":"R A.; Hu J.; Momeen M.U.; Tuning of electronic, optical and lipophilic behaviours of adamantane through various substitutions. Mater Res Express  2025,12(1),015404","journal-title":"Mater Res Express"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"115670","DOI":"10.1016\/j.ejmech.2023.115670","volume":"259","author":"Gutti G.","year":"2023","unstructured":"Gutti G.; Leifeld J.; Kakarla R.; Bajad N.G.; Ganeshpurkar A.; Kumar A.; Krishnamurthy S.; Klein-Schmidt C.; Tapken D.; Hollmann M.; Singh S.K.; Discovery of triazole-bridged aryl adamantane analogs as an intriguing class of multifunctional agents for treatment of Alzheimer\u2019s disease. Eur J Med Chem  2023,259,115670","journal-title":"Eur J Med Chem"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/S0022-5347(17)69964-6","volume":"55","author":"Carroll G.","year":"1946","unstructured":"Carroll G.; Allen H.N.; The treatment of urinary infections with mandelamine (methenamine mandelate); a clinical study of 200 cases. J Urol  1946,55(6),674-681","journal-title":"J Urol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"531","DOI":"10.3390\/md22120531","volume":"22","author":"Zhang X.","year":"2024","unstructured":"Zhang X.; Qiao K.; Cui R.; Xu M.; Cai S.; Huang Q.; Liu Z.; Tetrodotoxin: The state-of-the-art progress in characterization, detection, biosynthesis, and transport enrichment. Mar Drugs  2024,22(12),531","journal-title":"Mar Drugs"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.3390\/life13081655","volume":"13","author":"Baumgartner T.J.","year":"2023","unstructured":"Baumgartner T.J.; Haghighijoo Z.; Goode N.A.; Dvorak N.M.; Arman P.; Laezza F.; Voltage-gated Na+ channels in Alzheimer\u2019s disease: Physiological roles and therapeutic potential. Life  2023,13(8),1655","journal-title":"Life"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"e13593","DOI":"10.1111\/acel.13593","volume":"21","author":"Yuan D.J.","year":"2022","unstructured":"Yuan D.J.; Yang G.; Wu W.; Li Q.F.; Xu D.; Ntim M.; Jiang C.Y.; Liu J.C.; Zhang Y.; Wang Y.Z.; Zhu D.D.; Kundu S.; Li A.P.; Xiao Z.C.; Ma Q.H.; Li S.; Reducing Nav1.6 expression attenuates the pathogenesis of Alzheimer\u2019s disease by suppressing BACE1 transcription. Aging Cell  2022,21(5),e13593","journal-title":"Aging Cell"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/j.bbrc.2020.06.123","volume":"529","author":"Dembitsky V.M.","year":"2020","unstructured":"Dembitsky V.M.; Gloriozova T.A.; Poroikov V.V.; Pharmacological profile of natural and synthetic compounds with rigid adamantane-based scaffolds as potential agents for the treatment of neurodegenerative diseases. Biochem Biophys Res Commun  2020,529(4),1225-1241","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.bbadis.2016.11.020","volume":"1863","author":"Gazova Z.","year":"2017","unstructured":"Gazova Z.; Soukup O.; Sepsova V.; Siposova K.; Drtinova L.; Jost P.; Spilovska K.; Korabecny J.; Nepovimova E.; Fedunova D.; Horak M.; Kaniakova M.; Wang Z.J.; Hamouda A.K.; Kuca K.; Multi-target-directed therapeutic potential of 7-methoxytacrine-adamantylamine heterodimers in the Alzheimer\u2019s disease treatment. Biochim Biophys Acta Mol Basis Dis  2017,1863(2),607-619","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"637392","DOI":"10.3389\/fendo.2021.637392","volume":"12","author":"Tseng C.H.","year":"2021","unstructured":"Tseng C.H.; Vildagliptin has a neutral association with dementia risk in type 2 diabetes patients. Front Endocrinol  2021,12,637392","journal-title":"Front Endocrinol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"1138499","DOI":"10.3389\/fphar.2023.1138499","volume":"14","author":"Wang Y.","year":"2023","unstructured":"Wang Y.; Hu H.; Liu X.; Guo X.; Hypoglycemic medicines in the treatment of Alzheimer\u2019s disease: Pathophysiological links between AD and glucose metabolism. Front Pharmacol  2023,14,1138499","journal-title":"Front Pharmacol"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"976799","DOI":"10.3389\/fphar.2022.976799","volume":"13","author":"Behl T.","year":"2022","unstructured":"Behl T.; Kaur D.; Sehgal A.; Singla R.K.; Makeen H.A.; Albratty M.; Alhazmi H.A.; Meraya A.M.; Bungau S.; Therapeutic insights elaborating the potential of retinoids in Alzheimer\u2019s disease. Front Pharmacol  2022,13,976799","journal-title":"Front Pharmacol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"e57548","DOI":"10.7759\/cureus.57548","volume":"16","author":"Alsharief M.","year":"2024","unstructured":"Alsharief M.; How do retinoids affect Alzheimer\u2019s disease and can they be novel drug candidates? Cureus  2024,16(4),e57548","journal-title":"Cureus"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3390\/ph13090217","volume":"13","author":"Rusu A.","year":"2020","unstructured":"Rusu A.; Tanase C.; Pascu G.A.; Todoran N.; Recent advances regarding the therapeutic potential of adapalene. Pharmaceuticals  2020,13(9),217","journal-title":"Pharmaceuticals"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"16901","DOI":"10.3390\/ijms242316901","volume":"24","author":"Maines L.W.","year":"2023","unstructured":"Maines L.W.; Keller S.N.; Smith C.D.; Opaganib (ABC294640) induces immunogenic tumor cell death and enhances checkpoint antibody therapy. Int J Mol Sci  2023,24(23),16901","journal-title":"Int J Mol Sci"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"9645","DOI":"10.1523\/JNEUROSCI.0524-19.2019","volume":"39","author":"Lei M.","year":"2019","unstructured":"Lei M.; Teo J.D.; Song H.; McEwen H.P.; Yup Lee J.; Couttas T.A.; Duncan T.; Chesworth R.; Bertz J.; Przybyla M.; Van Eersel J.; Heng B.; Guillemin G.J.; Ittner L.M.; Fath T.; Garner B.; Ittner A.; Karl T.; Don A.S.; Sphingosine kinase 2 potentiates amyloid deposition but protects against hippocampal volume loss and demyelination in a mouse model of Alzheimer\u2019s disease. J Neurosci  2019,39(48),9645-9659","journal-title":"J Neurosci"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"100510","DOI":"10.1016\/j.jlr.2024.100510","volume":"65","author":"Komai M.","year":"2024","unstructured":"Komai M.; Noda Y.; Ikeda A.; Kaneshiro N.; Kamikubo Y.; Sakurai T.; Uehara T.; Takasugi N.; Nuclear SphK2\/S1P signaling is a key regulator of ApoE production and A\u03b2 uptake in astrocytes. J Lipid Res  2024,65(3),100510","journal-title":"J Lipid Res"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"117592","DOI":"10.1016\/j.ejmech.2025.117592","volume":"291","author":"Dane C.","year":"2025","unstructured":"Dane C.; Montgomery A.P.; Kassiou M.; The adamantane scaffold: Beyond a lipophilic moiety. Eur J Med Chem  2025,291,117592","journal-title":"Eur J Med Chem"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1021\/acschemneuro.0c00719","volume":"12","author":"Sait A.","year":"2021","unstructured":"Sait A.; Angeli C.; Doig A.J.; Day P.J.R.; Viral involvement in Alzheimer\u2019s disease. ACS Chem Neurosci  2021,12(7),1049-1060","journal-title":"ACS Chem Neurosci"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13195-021-00950-0","volume":"14","author":"Linard M.","year":"2022","unstructured":"Linard M.; Bezin J.; Hucteau E.; Joly P.; Garrigue I.; Dartigues J.F.; Pariente A.; Helmer C.; Antiherpetic drugs: A potential way to prevent Alzheimer\u2019s disease? Alzheimers Res Ther  2022,14(1),3","journal-title":"Alzheimers Res Ther"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S0892-0362(01)00119-2","volume":"23","author":"Iezhitsa I.N.","year":"2001","unstructured":"Iezhitsa I.N.; Spasov A.A.; Bugaeva L.I.; Effects of bromantan on offspring maturation and development of reflexes. Neurotoxicol Teratol  2001,23(2),213-222","journal-title":"Neurotoxicol Teratol"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.neuropharm.2007.07.001","volume":"53","author":"Mikhaylova M.","year":"2007","unstructured":"Mikhaylova M.; Vakhitova J.; Yamidanov R.; Salimgareeva M.; Seredenin S.; Behnisch T.; The effects of ladasten on dopaminergic neurotransmission and hippocampal synaptic plasticity in rats. Neuropharmacology  2007,53(5),601-608","journal-title":"Neuropharmacology"},{"key":"ref=58","first-page":"910","volume":"75","author":"Kamianov I.M.","year":"1975","unstructured":"Kamianov I.M.; Andrezinia R.A.; The antiparkinson activity of gludantan (preliminary report). Zh Nevropatol Psikhiatr Im S S Korsakova  1975,75(6),910-916","journal-title":"Zh Nevropatol Psikhiatr Im S S Korsakova"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1007\/s10517-015-2968-8","volume":"159","author":"Ivanova E.A.","year":"2015","unstructured":"Ivanova E.A.; Kapitsa I.G.; Val\u2019dman E.A.; Voronina T.A.; Anti-parkinsonian activity of hemantane on a model of hemiparkinsonian syndrome in rats. Bull Exp Biol Med  2015,159(3),380-383","journal-title":"Bull Exp Biol Med"},{"key":"ref=60","first-page":"241","volume":"14","author":"Ivanova E.","year":"2024","unstructured":"Ivanova E.; Matyushkin A.; Sorokina A.; Alexeeva S.; Miroshkina I.; Kachalov K.; Voronina T.; Durnev A.; Low-affinity NMDA receptor antagonist hemantane in a topical formulation attenuates arthritis induced by freund\u2019s complete adjuvant in rats. Adv Pharm Bull  2024,14(1),241-252","journal-title":"Adv Pharm Bull"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1007\/s10517-017-3946-0","volume":"164","author":"Kolik L.G.","year":"2017","unstructured":"Kolik L.G.; Nadorova A.V.; Seredenin S.B.; Non-competitive NMDA receptor antagonist hemantane reduces ethanol consumption in long-term alcohol experienced rats. Bull Exp Biol Med  2017,164(2),152-157","journal-title":"Bull Exp Biol Med"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"9438","DOI":"10.1039\/D4SC01136H","volume":"15","author":"Rinn N.","year":"2024","unstructured":"Rinn N.; Rojas-Le\u00f3n I.; Peerless B.; Gowrisankar S.; Ziese F.; Rosemann N.W.; Pilgrim W.C.; Sanna S.; Schreiner P.R.; Dehnen S.; Adamantane-type clusters: Compounds with a ubiquitous architecture but a wide variety of compositions and unexpected materials properties. Chem Sci  2024,15(25),9438-9509","journal-title":"Chem Sci"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3233\/JAD-2008-13110","volume":"13","author":"Bakchine S.","year":"2008","unstructured":"Bakchine S.; Loft H.; Memantine treatment in patients with mild to moderate Alzheimer\u2019s disease: Results of a randomised, double-blind, placebo-controlled 6-month study. J Alzheimers Dis  2008,13(1),97-107","journal-title":"J Alzheimers Dis"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"5744","DOI":"10.3390\/molecules29235744","volume":"29","author":"Puranik N.","year":"2024","unstructured":"Puranik N.; Song M.; Glutamate: Molecular mechanisms and signaling pathway in Alzheimer\u2019s disease, a potential therapeutic target. Molecules  2024,29(23),5744","journal-title":"Molecules"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"7452","DOI":"10.3390\/ijms21207452","volume":"21","author":"Bukke V.N.","year":"2020","unstructured":"Bukke V.N.; Archana M.; Villani R.; Romano A.D.; Wawrzyniak A.; Balawender K.; Orkisz S.; Beggiato S.; Serviddio G.; Cassano T.; The dual role of glutamatergic neurotransmission in Alzheimer\u2019s disease: From pathophysiology to pharmacotherapy. Int J Mol Sci  2020,21(20),7452","journal-title":"Int J Mol Sci"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"3516","DOI":"10.1021\/cr100264t","volume":"113","author":"Wanka L.","year":"2013","unstructured":"Wanka L.; Iqbal K.; Schreiner P.R.; The lipophilic bullet hits the targets: Medicinal chemistry of adamantane derivatives. Chem Rev  2013,113(5),3516-3604","journal-title":"Chem Rev"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"e14638","DOI":"10.1111\/cbdd.14638","volume":"104","author":"Singh Y.P.","year":"2024","unstructured":"Singh Y.P.; Kumar H.; Recent advances in medicinal chemistry of memantine against Alzheimer\u2019s disease. Chem Biol Drug Des  2024,104(4),e14638","journal-title":"Chem Biol Drug Des"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/S1474-4422(21)00249-0","volume":"20","author":"Rascol O.","year":"2021","unstructured":"Rascol O.; Fabbri M.; Poewe W.; Amantadine in the treatment of Parkinson\u2019s disease and other movement disorders. Lancet Neurol  2021,20(12),1048-1056","journal-title":"Lancet Neurol"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"1439115","DOI":"10.3389\/fphar.2024.1439115","volume":"15","author":"Yang Y.","year":"2024","unstructured":"Yang Y.; Wei S.; Tian H.; Cheng J.; Zhong Y.; Zhong X.; Huang D.; Jiang C.; Ke X.; Adverse event profile of memantine and donepezil combination therapy: A real-world pharmacovi-gilance analysis based on FDA adverse event reporting system (FAERS) data from 2004 to 2023. Front Pharmacol  2024,15,1439115","journal-title":"Front Pharmacol"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1021\/acs.orglett.5b00100","volume":"17","author":"Liao Y.","year":"2015","unstructured":"Liao Y.; Liu X.; Yang J.; Lao Y.Z.; Yang X.W.; Li X.N.; Zhang J.J.; Ding Z.; Xu H.X.; Xu G.; Hypersubones A and B, new polycyclic acylphloroglucinols with intriguing adamantane type cores from Hypericum subsessile. Org Lett  2015,17(5),1172-1175","journal-title":"Org Lett"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"e12627","DOI":"10.1002\/emp2.12627","volume":"2","author":"Kakehi E.","year":"2021","unstructured":"Kakehi E.; Matsumoto M.; Taniguchi S.; Akamatsu Y.; Sakurai S.; Hirotani A.; Nozaki T.; Shoji K.; Adachi S.; Kotani K.; Matsumura M.; Reversible cerebral vasoconstriction syndrome associated with tetrodotoxin poisoning: A case report. J Am Coll Emerg Physicians Open  2021,2(6),e12627","journal-title":"J Am Coll Emerg Physicians Open"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"1269344","DOI":"10.3389\/fcimb.2023.1269344","volume":"13","author":"Meseko C.","year":"2023","unstructured":"Meseko C.; Sanicas M.; Asha K.; Sulaiman L.; Kumar B.; Antiviral options and therapeutics against influenza: History, latest developments and future prospects. Front Cell Infect Microbiol  2023,13,1269344","journal-title":"Front Cell Infect Microbiol"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"3245","DOI":"10.2174\/0929867323666160525114026","volume":"23","author":"Spilovska K.","year":"2016","unstructured":"Spilovska K.; Zemek F.; Korabecny J.; Nepovimova E.; Soukup O.; Windisch M.; Kuca K.; Adamantane \u2013 A lead structure for drugs in clinical practice. Curr Med Chem  2016,23(29),3245-3266","journal-title":"Curr Med Chem"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"446","DOI":"10.4062\/biomolther.2012.20.5.446","volume":"20","author":"Oliynyk S.","year":"2012","unstructured":"Oliynyk S.; Oh S.K.; The pharmacology of actoprotectors: Practical application for improvement of mental and physical performance. Biomol Ther  2012,20(5),446-456","journal-title":"Biomol Ther"}],"container-title":["Mini-Reviews in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113895575426460260130103605","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/251125\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113895575426460260130103605","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:07:30Z","timestamp":1790914050000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/251125\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":74,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0113895575426460260130103605","relation":{},"ISSN":["1389-5575"],"issn-type":[{"value":"1389-5575","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2025-07-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-15","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}